VESPA
13.2.2024 15:01:32 CET | Business Wire | Press release
Vespa, supplier of the leading platform for applications that leverage AI and data online at scale, today announced it has earned recognition as a leader and forward mover in the GigaOm Sonar for Vector Databases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213670564/en/
GigaOm Sonar Reports evaluate technology that is new, interesting, and attractive but poses intrinsic risk when it comes to enterprise adoption. These reports give you the right information at the right time to help plan your strategy. Vespa is positioned as a Leader and Forward Mover in GigaOm's latest report on vector databases. (Graphic: Business Wire)
The research cites Vespa as a platform leader “because of its widespread embedding flexibility, rapid time for updating, and hybrid search capabilities–with neural network rankings. These are critical to maximizing the ROI for vector similarity search engines.”
Andrew Brust, Analyst, GigaOm: “Interest in the vector database market is surging as industries seek advanced AI to manage vast unstructured data. Vespa is well placed in this market with strengths that include model versatility, search flexibility and real-time capabilities.”
Daniel Doro, Director of Engineering, Search, Spotify: “As a reliable and scalable solution, Vespa has been instrumental in enabling Search at Spotify. We look forward to continuing our work with the Vespa team and enabling innovation that will enhance the experience for Spotify listeners.”
Jungwon Byun, COO & Cofounder, Elicit: “Vespa is a battle-tested platform that allows us to integrate keyword and vector search seamlessly. It forms a key part of our AI research solution, guaranteeing precision and rapidity in streamlining research processes. We highly recommend Vespa for its reliability and efficiency.”
Jon Bratseth, CEO and Founder, Vespa: “We are pleased to be recognized as a leader in an emerging, highly relevant, and rapidly growing market. AI is getting significant attention for its role in solving today's data challenges found in eCommerce, digital media, financial services and other industries. Vespa enables organizations to realize this opportunity. GigaOm brings clarity to this crowded and hype laden market.”
In October 2023, Vespa was spun out from Yahoo as an independent company, although the technology has existed for over a decade. Yahoo remains a key investor with Vespa technology underpinning approximately 150 applications that are integral to Yahoo’s operations.
The GigaOm Sonar for Vector Databases can be downloaded here:
https://content.vespa.ai/gigaom-report-2024
About Vespa
Vespa is a platform for applications which leverage AI and data to deliver experiences to end users online in real time, such as search, recommendation, personalization, and retrieval-augmented generation (RAG). Vespa automatically organizes data, inference and logic to allow applications to work with any amount of data, queries, and is available both as a managed service and as open source.
About Elicit
Elicit is the first AI research assistant using language models to automate research workflows like literature review. Over 250,000 researchers in leading academic and industry labs around the world use Elicit every month to summarize papers and extract insights at scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213670564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom